Agios Pharmaceuticals Inc (NASDAQ:AGIO) has earned a consensus rating of “Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $68.77.
A number of equities analysts have weighed in on the stock. Guggenheim raised their target price on shares of Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a “buy” rating in a research note on Monday, June 15th. Citigroup raised their target price on shares of Agios Pharmaceuticals from $64.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, June 15th. ValuEngine downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Piper Sandler raised their target price on shares of Agios Pharmaceuticals from $70.00 to $80.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Finally, Cantor Fitzgerald raised their target price on shares of Agios Pharmaceuticals from $70.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, July 31st.
AGIO stock traded up $0.52 during trading on Wednesday, reaching $38.80. The company had a trading volume of 442 shares, compared to its average volume of 549,445. Agios Pharmaceuticals has a 52 week low of $27.77 and a 52 week high of $56.74. The company has a market cap of $2.65 billion, a P/E ratio of -7.21 and a beta of 1.86. The business has a 50 day moving average of $41.52 and a 200 day moving average of $44.93.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.36) by $0.05. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The company had revenue of $37.30 million during the quarter, compared to the consensus estimate of $37.17 million. During the same period in the prior year, the firm earned ($1.87) earnings per share. Agios Pharmaceuticals’s revenue was up 42.4% on a year-over-year basis. Analysts forecast that Agios Pharmaceuticals will post -4.58 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in AGIO. M&T Bank Corp acquired a new position in Agios Pharmaceuticals during the first quarter worth about $10,644,000. Advisor Group Holdings Inc. boosted its stake in Agios Pharmaceuticals by 427.9% in the 2nd quarter. Advisor Group Holdings Inc. now owns 1,267 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 1,027 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $75,000. Citizens Financial Group Inc RI boosted its stake in Agios Pharmaceuticals by 919.3% in the 2nd quarter. Citizens Financial Group Inc RI now owns 1,478 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 1,333 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in Agios Pharmaceuticals by 1,510.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,562 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,465 shares in the last quarter. 95.21% of the stock is owned by institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
See Also: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.